Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development.

Biotechnology

Aristea Therapeutics

James Mackay

Sara McCutchan

Deanne Reid

Nihar Bhakta

The board of directors at Aristea Therapeutics is experienced in many different aspects of the business world including being a partner at Novo Ventures, a senior market planning manager at Genentech, and a senior life sciences specialist at L.E.K. Consulting. They are also experienced in the academic world, coming from Yale University and Texas Tech University with degrees in Pharmacology and Molecular Biology respectively.

Board of Directors

About

Team members

Other teams at Aristea Therapeutics

Leadership Team

CEO and Executive Team